Futureproofing [18F]Fludeoxyglucose manufacture at an Academic Medical Center

EJNMMI Radiopharmacy and Chemistry

Isaac M Jackson¹  Jenelle Stauff¹  Peter J H Scott¹  Timothy J Desmond¹  Wade P Winton¹  Jonathan M Pham¹  Jeremiah Alicea¹  Brian G Hockley¹  Robert A Koeppe¹  Virginia E Rogers¹  Anthony J Mufarreh¹  Maria V Fawaz¹  Bradford D Henderson¹  Alexandra R Sowa¹ 

[1] Department of Radiology, University of Michigan;

关键词: PET radiochemistry;    Cyclotron targetry;    Fludeoxyglucose (FDG);    Fluorine-18;    Automation;   

DOI  :  10.1186/s41181-018-0048-x

来源: DOAJ

【 摘 要 】

Abstract Background We recently upgraded our [18F]fludeoxyglucose (FDG) production capabilities with the goal of futureproofing our FDG clinical supply, expanding the number of batches of FDG we can manufacture each day, and improving patient throughput in our nuclear medicine clinic. In this paper we report upgrade of the synthesis modules to the GE FASTLab 2 platform (Phase 1) and cyclotron updates (Phase 2) from both practical and regulatory perspectives. We summarize our experience manufacturing FDG on the FASTLab 2 module with a high-yielding self-shielded niobium (Nb) fluorine-18 target. Results Following installation of Nb targets for production of fluorine-18, a 55 μA beam for 22 min generated 1330 ± 153 mCi of [18F]fluoride. Using these cyclotron beam parameters in combination with the FASTLab 2, activity yields (AY) of FDG were 957 ± 102 mCi at EOS, corresponding to 72% non-corrected AY (n = 235). Our workflow, inventory management and regulatory compliance have been greatly simplified following the synthesis module and cyclotron upgrades, and patient wait times for FDG PET have been cut in half at our nuclear medicine clinic. Conclusions The combination of FASTlab 2 and self-shielded Nb fluorine-18 targets have improved our yield of FDG, and enabled reliable and repeatable manufacture of the radiotracer for clinical use.

【 授权许可】

Unknown